AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance

Go back to AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance

AbbVie (ABBV) Highlights New Investigational Data for Elagolix at 2018 ACOG Meetings

April 27, 2018 8:10 AM EDT

AbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.

"We strive to improve care for women living with endometriosis and uterine fibroids," said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. "These presentations highlight safety and efficacy data for elagolix and... More

Abbvie (ABBV) PT Raised to $101 at Deutsche Bank

April 27, 2018 7:49 AM EDT

Deutsche Bank raised its price target on Abbvie (NYSE: ABBV) to $101.00 (from $100.00) while maintaining a Hold rating.

... More

AbbVie (ABBV) Plans $7.5B Tender Offer

April 26, 2018 7:52 AM EDT

With earnings, AbbVie (NYSE: ABBV) said it plans to commence a tender offer to purchase for cash up to $7.5 billion in value of shares of its common stock through a modified "Dutch auction" tender offer at a specified price range to be determined.... More